SCT

Across TCGA pan-cancer cohorts, SCT RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of SCT’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where SCT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SCT is over-expressed in tumor, although a few such as KICH and STAD show the opposite, repressed pattern.

BRCA, LUAD, and KICH are the cancer types where SCT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SCT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	III,IV	+2.025	<.001	6	view →
LUAD	Female	II,III,IV	+1.344	<.001	6	view →
KICH	All	All	−0.576	<.001	5	view →
LUSC	All	All	+0.508	.003	4	view →
HNSC	Female	All	+1.626	.021	3	view →
ESCA	All	II,III,IV	+2.285	.001	2	view →
STAD	Male	All	−0.910	.016	2	view →
CHOL	Male	All	+0.806	.004	2	view →
PRAD	All	All	−0.424	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

SCT–BRCA

Open the BRCA breakdown →